To help migraine patients — and sell more medicines — major drugmakers turn to telehealth

Taking stock of the drug industry, from the lab to the medicine chest

August 27, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | To help migraine patients — and sell more medicines — major drugmakers turn to telehealth Migraine drugs will be a focus of new online portal as Pfizer joins Eli Lilly and other pharmaceutical companies in turning to direct-to-consumer websites. By Katie Palmer STAT+ | Lilly launches Zepbound vials in move that could ease supply constraints Dosages of Zepbound pens go up to 10 and 15 mg, but Lilly is only offering low-doses vials for now. By Elaine Chen Opinion: The importance of reducing the financial burden of participating in clinical trials Some clinical trial sponsors are reluctant to provide financial support because of the current legal landscape. Congress can fix it. By Jim Murphy and Lisa Lacasse

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser